NCT04880434

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 95 (actual)
• Sponsor: Kite, A Gilead Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (KTE-X19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL).

Detailed description

Study KTE-C19-102 (NCT02601313) enrolled participants with r/r MCL who have been treated with up to 5 prior regimens including a Bruton's tyrosine kinase inhibitor (BTKi) in Cohort 1 and Cohort 2. However, to fulfill FDA Postmarketing Requirement Cohort 3 is added to the study. It will include participants with r/r MCL who have been treated with up to 5 prior regimens but have not received prior therapy with a BTKi. The primary analysis in Cohort 1 and Cohort 2 is already completed. Data for Cohort 3 will be analyzed separately. Therefore, this separate registration is only for Cohort 3. After the end of KTE-C19-102, subjects who received an infusion of anti-CD19 CAR T cells will complete the remainder of the 15-year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968

Conditions

• Relapsed/Refractory Mantle Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Fludarabine	Administered intravenously
DRUG	Cyclophosphamide	Administered intravenously
BIOLOGICAL	Brexucabtagene autoleucel	A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells

Timeline

• Start date: 2021-04-27
• Primary completion: 2025-06-17
• Completion: 2025-06-17
• First posted: 2021-05-10
• Last updated: 2025-11-17

Locations

40 sites across 6 countries: United States, France, Germany, Netherlands, Spain, United Kingdom

Regulatory

• FDA-regulated drug study